Thus, target treatment on RIPK2 showed an ideal control of inflammatory diseases, such as cystic fibrosis, asthma, inflammatory bowel disease and pancreatitis [3, 25, 26]. This evidence concerns the gene RIPK2 and inflammatory bowel disease.